EvoMG Program
@evomg-bcn.bsky.social
The Evolutionary Medical Genomics (EvoMG) Program is a joint initiative by the CRG, UPF and IBE in Barcelona to boost biomedical research by applying evolutionary approaches.
Website: https://t.co/MBCtzyi8jt
Website: https://t.co/MBCtzyi8jt
Reposted by EvoMG Program
At the @melisupf.bsky.social, @mirimiam.bsky.social would like to recruit two fully-funded #PhDcandidate for the #MSCA Doctoral Network @evomg-dn.bsky.social.
#AcademicSky #ResearchJobs
#AcademicSky #ResearchJobs
🚨🚨🚨
Two super well-funded PhD grants from our MSCA Doctoral Network @evomg-dn.bsky.social at our lab at @melisupf.bsky.social, @crg.eu and the @evomg-bcn.bsky.social Program.
If you're excited about evolution, genomics and biomedical research, this is your DN! 😃
Further info: www.evomg-dn.eu and 👇
Two super well-funded PhD grants from our MSCA Doctoral Network @evomg-dn.bsky.social at our lab at @melisupf.bsky.social, @crg.eu and the @evomg-bcn.bsky.social Program.
If you're excited about evolution, genomics and biomedical research, this is your DN! 😃
Further info: www.evomg-dn.eu and 👇
EVOMG-DN
EvoMG-DN is a European Doctoral Network funded by the Horizon Europe Marie Skłodowska-Curie Actions (MSCA), composed of 14 beneficiaries and associated partners from both academic and non-academic sectors.
www.evomg-dn.eu
October 15, 2025 at 11:09 AM
At the @melisupf.bsky.social, @mirimiam.bsky.social would like to recruit two fully-funded #PhDcandidate for the #MSCA Doctoral Network @evomg-dn.bsky.social.
#AcademicSky #ResearchJobs
#AcademicSky #ResearchJobs
Reposted by EvoMG Program
The second is about potential fitness costs of cancer drug resistance, and how we might exploit them using approaches like adaptive therapy. (building on our work with @mlockley.bsky.social in ovarian cancer: aacrjournals.org/cancerres/ar...). Description here: www.icr.ac.uk/study-and-ca...
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
Carboplatin adaptive therapy improves treatment efficacy without increasing daily dose due to reduced fitness of drug-resistant populations, which can be tracked using cfDNA and could direct adaptive ...
aacrjournals.org
October 14, 2025 at 8:26 PM
The second is about potential fitness costs of cancer drug resistance, and how we might exploit them using approaches like adaptive therapy. (building on our work with @mlockley.bsky.social in ovarian cancer: aacrjournals.org/cancerres/ar...). Description here: www.icr.ac.uk/study-and-ca...
And last but not least, closing this very intense meeting, Jesús Perez-Losada, from iBMCC, told us about their work on molecular and genetic determinants of cancer susceptibility, evolution, and treatment response.
October 12, 2025 at 4:04 PM
And last but not least, closing this very intense meeting, Jesús Perez-Losada, from iBMCC, told us about their work on molecular and genetic determinants of cancer susceptibility, evolution, and treatment response.
Next, Solip Park, from CNIO ( @cniostopcancer.bsky.social ), spoke about her work in context-specific cancer fitness landscapes and protein-protein interactions.
October 12, 2025 at 4:04 PM
Next, Solip Park, from CNIO ( @cniostopcancer.bsky.social ), spoke about her work in context-specific cancer fitness landscapes and protein-protein interactions.
Next, Rosa Fernández ( @rosafernandez.bsky.social ), from the EvoMG Program and @ibe-barcelona.bsky.social, gave her flash talk about genome evolution in annelids and how they could be novel models to understand genomic instability events in cancer.
October 12, 2025 at 4:04 PM
Next, Rosa Fernández ( @rosafernandez.bsky.social ), from the EvoMG Program and @ibe-barcelona.bsky.social, gave her flash talk about genome evolution in annelids and how they could be novel models to understand genomic instability events in cancer.
Then, Ferran Nadeu ( @ferrannadeu.bsky.social ), from IDIBAPS ( @idibaps.bsky.social ), told us about his work on origin and immuno-genomic forces driving multiple and independent CLL expansions.
October 12, 2025 at 4:04 PM
Then, Ferran Nadeu ( @ferrannadeu.bsky.social ), from IDIBAPS ( @idibaps.bsky.social ), told us about his work on origin and immuno-genomic forces driving multiple and independent CLL expansions.
Next, Donate Weghorn ( @weghornlab.bsky.social ), from the EvoMG Program and @crg.eu, talked about her work on mutational processes and selection in cancer.
October 12, 2025 at 4:04 PM
Next, Donate Weghorn ( @weghornlab.bsky.social ), from the EvoMG Program and @crg.eu, talked about her work on mutational processes and selection in cancer.
And the last speaker of the session was Marc de Manuel ( @marcdemanuel.bsky.social ), from the EvoMG Program and @ibe-barcelona.bsky.social presenting his work on mutation.
October 12, 2025 at 3:50 PM
And the last speaker of the session was Marc de Manuel ( @marcdemanuel.bsky.social ), from the EvoMG Program and @ibe-barcelona.bsky.social presenting his work on mutation.